Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
4.730
-0.290 (-5.78%)
At close: Nov 7, 2025, 4:00 PM EST
4.790
+0.060 (1.27%)
After-hours: Nov 7, 2025, 7:56 PM EST
Nuvation Bio Employees
Nuvation Bio had 220 employees as of December 31, 2024. The number of employees increased by 169 or 331.37% compared to the previous year.
Employees
220
Change (1Y)
169
Growth (1Y)
331.37%
Revenue / Employee
$121,582
Profits / Employee
-$988,545
Market Cap
1.62B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 220 | 169 | 331.37% |
| Dec 31, 2023 | 51 | -2 | -3.77% |
| Dec 31, 2022 | 53 | -11 | -17.19% |
| Dec 31, 2021 | 64 | 28 | 77.78% |
| Dec 31, 2020 | 36 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
NUVB News
- 2 days ago - Nuvation Bio: Ibtrozi's Rollout So Far Confirms Bullish Case - Seeking Alpha
- 6 days ago - Nuvation Bio Inc. (NUVB) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Nuvation Bio Reports Third Quarter 2025 Financial Results and Provides Business Update - Business Wire
- 10 days ago - Nuvation Bio to Participate in Upcoming Investor Conferences - Business Wire
- 17 days ago - Nuvation Bio Enrolls First Patient in Global, Randomized Study of Safusidenib for Maintenance Treatment of High-Grade IDH1-Mutant Glioma - Business Wire
- 20 days ago - Nuvation Bio to Report Third Quarter 2025 Financial Results and Provide Business Update on November 3, 2025 - Business Wire
- 5 weeks ago - Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer - Business Wire
- 5 weeks ago - 3 Of My Favorite Biotech Stocks Under $10 - Seeking Alpha